Development of TLR9 agonists for cancer therapy
Open accessThe DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Abstract
In vertebrates, the TLRs are a family of specialized immune receptors that induce protective immune responses when they detect highly conserved pathogen-expressed molecules.Synthetic agonists for several TLRs, including TLR3, TLR4, TLR7, TLR8, and TLR9, have been or are being developed for the treatment of cancer.TLR9 detects the unmethylated CpG dinucleotides prevalent in bacterial and viral DNA but not in vertebrate genomes.As discussed in this Review, short synthetic oligodeoxynucleotides containing these immune stimulatory CpG motifs activate TLR9 in vitro and in vivo, inducing innate and adaptive immunity, and are currently being tested in multiple phase II and phase III human clinical trials as adjuvants to cancer vaccines and in combination with conventional chemotherapy and other therapies.Nonstandard abbreviations used: CpG ODN, oligodeoxynucleotide(s) containing one or more unmethylated CpG dinucleotides; HBsAg, HBV surface antigen; IFA, incomplete Freund's adjuvant; KLH, keyhole limpet hemocyanin; MART1, melanoma-associated antigen recognized by T cells 1; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung carcinoma; ODN, oligodeoxynucleotide; pDC, plasmacytoid DC; PS, phosphorothioate; PS ODN, ODN that have a nuclease-resistant phosphorothioate backbone.Conflict of interest: A.M. Krieg is a founder and employee of and shareholder in Coley Pharmaceutical Group and has a financial interest in the development of TLR9 agonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 2×
“TLR9 seems to be required for all the immune stimulatory responses to synthetic PS ODN, since there is a complete loss of activity in mice genetically deficient for TLR9 (6, 8, 9).”
BackgroundTakeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 1×
“Third, etoposide and mitomycin C have recently been reported to cause calreticulin to be exposed on the surface of apoptotic tumor cells, conferring on them immunogenicity to an immune therapy (115).”
BackgroundCancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Toll Pathway-Dependent Blockade of CD4 + CD25 + T Cell-Mediated Suppression by Dendritic Cells
Pasare, C., & Medzhitov, R. (2003) · Science · doi:10.1126/science.1078231 · Cited by 1,997
IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors
Liu, Y.-J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115633 · Cited by 1,625
Cited by
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Intestinal Bacteria and the Regulation of Immune Cell Homeostasis
Hill, D. A., & Artis, D. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101330 · Cited by 586
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Melero, I., Castanon, E., Alvarez, M., Champiat, S., & Marabelle, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00507-y · Cited by 493
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Infection-mimicking materials to program dendritic cells in situ
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G., & Mooney, D. J. (2009) · Nature Materials · doi:10.1038/nmat2357 · Cited by 434
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer
Krieg, A. M. (2008) · Oncogene · doi:10.1038/sj.onc.1210911 · Cited by 388
Self-citationTLR9 as a key receptor for the recognition of DNA☆
KUMAGAI, Y., TAKEUCHI, O., & AKIRA, S. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.12.004 · Cited by 387
TLR signaling by tumor and immune cells: a double-edged sword
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210904 · Cited by 377
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Urban-Wojciuk, Z., Khan, M. M., Oyler, B. L., Fåhraeus, R., Marek-Trzonkowska, N., Nita-Lazar, A., Hupp, T. R., & Goodlett, D. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02388 · Cited by 307
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295
Liu, M., O’Connor, R. S., Trefely, S., Graham, K., Snyder, N. W., & Beatty, G. L. (2019) · Nature Immunology · doi:10.1038/s41590-018-0292-y · Cited by 294
Miller, L. S. (2008) · Advances in Dermatology · doi:10.1016/j.yadr.2008.09.004 · Cited by 275
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity
Büll, C., Boltje, T. J., Balneger, N., Weischer, S. M., Wassink, M., van Gemst, J. J., Bloemendal, V. R., Boon, L., van der Vlag, J., Heise, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3376 · Cited by 268
Fukui, R., Saitoh, S.-I., Matsumoto, F., Kozuka-Hata, H., Oyama, M., Tabeta, K., Beutler, B., & Miyake, K. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082316 · Cited by 254
Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143
“For instance, TLR7 agonist imiquimod is used in treating basal cell and cutaneous malignancies; also, synthetic oligodeoxynucleotides containing unmethylated CpG motifs that activate TLR9 are in clinical trials (20, 21).”
Prophylactic and therapeutic implications of toll-like receptor ligands
Hedayat, M., Takeda, K., & Rezaei, N. (2012) · Medicinal Research Reviews · doi:10.1002/med.20214 · Cited by 76
Toll-like receptor agonists: a patent review (2011 - 2013)
Hussein, W. M., Liu, T.-Y., Skwarczynski, M., & Toth, I. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.880691 · Cited by 68
Mangsbo, S. M., Sanchez, J., Anger, K., Lambris, J. D., Ekdahl, K. N., Loskog, A. S., Nilsson, B., & Tötterman, T. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902374 · Cited by 42
“Three classes of synthetic ODNs (classes A, B, and C) are described where CpG ODN class B is the only ODN type assessed in clinical trials (1).”
Background
Metadata
- Authors
- Krieg, A. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-05-01
- Volume
- 117
- Issue
- 5
- Pages
- 1184-1194
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2117684163
- Cited by
- 429
- References
- 118
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.